OligoMedic is a privately held Canadian company created in 2010 and focused on developing and commercializing medical devices.

OligoMedic's founders are biomaterials experts who have developed several devices for the orthopedic market.

OligoMedic's technology is based on injectable thermosensitive hydrogels (thermogels) that solidify at body-temperature.

OligoMedic's leading product JointRep™ is CE-marked, and patented and granted in all major countries.

JointRep™ is presently distributed to the orthopedic market to repair cartilage, with spectacular success in over 1900 patients.

JointRep™ can also be used to deliver platelet rich plasma (PRP) or adipose derived mesenchymal stem cells for various orthopedic applications such as tendon and meniscus treatment.

Controlled post-market clinical study for use of JointRep™ in conjunction with microfracture in grade III-IV knee cartilage lesions showed exceptional results in terms of pain reduction and mobility improvement for patients, and MRI evidence of hyaline cartilage regrowth.

Don’t Replace, JointRep™ Preserves and Repairs

JointRep™ is an injectable implant. It is the first product to provide a minimally invasive curative treatment for traumatic or arthrosis cartilage defects of any size or grade. Established treatments at best alleviate pain and delay the progression of cartilage loss. Other less desirable alternatives include total joint replacement.


JointRep™ is being tested in a controlled clinical study in Europe, to compare a JointRep™ + microfracture operation to an operation with standard microfracture alone, on patients of ages 18-75 with grade III-IV cartilage lesions.

The WOMAC scores at 6 and 12 month endpoints demonstrate clear superiority of the operation with addition of JointRep™.

These results are substantiated with MRI evidence of genuine hyaline cartilage regrowth.

  • JointRep™ is a thermosensitive hydrogel that rapidly solidifies when heated to body temperature. It provides a biocompatible, isotonic and bioadhesive scaffold matrix.
  • JointRep™ is administered in a one-step procedure as part of a standard arthroscopy. It only adds a few minutes to the operation.
  • The operation is performed under local anesthesia and the patient is released the same day and allowed total load ambulation with contralateral crutch after 90 minutes.
  • JointRep™ can be applied to lesions of any size or shape in any joint.

JointRep rapidly forms a solid hydrogel when implanted in cartilage void.

  • No technical hurdles: JointRep™ should be stored between 2 and 8°C, but can be transported at ambient temperature.
  • Can be used without planning. Preparation time is between 3 and 5 minutes, enabling the physician to use it ad-hoc if defects are noticed in the course of a routine arthroscopic inspection or treatment (a study of over 30,000 arthroscopies in the United States has revealed an average of 2.7 defects in 63% of patients).
  • Unlike a viscosupplement, JointRep™ directly repairs affected cartilage.
  • JointRep™ is currently not licenced for sale in the USA and Canada.

Second look arthroscopy.

From left to right:

Defect in intercondylar notch prepared for JointRep™.   Defect filled with material.  Defect one year after.
1.Healthy cartilage 2.Defect.


Video Gallery

Arthroscopic lavage/debridement operation with JointRep™

This procedure is used to treat less severe chondropathies like symptomatic grade I-II osteoarthritis. There is no cartilage regrowth but lasting pain relief after 2-3 months. The age limit is 55.

With Dr. Nicolas Duval, Orthopedist

Standard Arthroscopic operation (Lavage/debridement)

Preparation and injection of JointRep™ implant

Arthroscopic JointRep™ operation with microfracture

This procedure is used to treat more severe chondropathies like grade III-IV osteoarthritis. The rehab period is very short, the pain relief is very quick and there is genuine regrowth of hyaline cartilage. The age limit is 75.

With Dr. Gennaro Pipino, full professor of orthopedic surgery, University of Lugano (Switzerland)

View from the operation room

Operation screen

Total weight ambulation with contralateral cane

90 minutes after the operation.

Demo: mixing JointRep™ components


One month after knee osteoarthritis treatment with microfracture + JointRep™.

A happy patient's post to Facebook three weeks after his microfracture + JointRep™.

News and Updates

Other clinical trials on different indications are planned and will be disclosed when protocols are defined. Planning formal clinical trials for intervertebral disc regeneration using JointRep™ mixed with autologous stem cells.

Preliminary steps taken toward procedures with FDA for market approval in the US.

Gaining market penetration in Europe, ANZ regions, Middle East, South East Asia, Central and South America including Brazil.

European controlled clinical trial: 60 patients, and comparing microfracture to microfracture & JointRep™. First study results will be published during Winter-2016.

Initial experimentation with JointRep™ and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.
Structured OligoMedic for strategic partnership and initiated clinical trials and post market evaluation.
Manufacturing, packaging, and shipping (at ambient temperature!) processes defined. Obtained CE mark in October.

Follow up pre-clinical study on Health Canada SAP.

Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep™ operation. 

We succeeded in premixing JointRep™ with platelet rich plasma (PRP) while maintaining all the product's properties. The same can be done with bone marrow extract. This opens the possibility of using JointRep™ to deliver PRP or adipose derived mesenchymal cells for various orthopedic applications such as tendon and meniscus treatment.


Video showing the mixing of B1 and B2 first, then the mixing of (B1+B2) with approximately 1 cc of PRP (or less) and finally the mixing of (B1+B2+ PRP) and A giving an injectable gel that solidifies with temperature as does JointRep™ alone.


Video showing the mixing of B1 and B2 first, then the mixing of (B1+B2) with approximately 1 cc of bone marrow extract (or less) and finally the mixing of (B1+B2+ PRP) and A giving an injectable gel that solidifies with temperature as does JointRep™ alone.

Management Team


Dr. Amine Selmani, PhD President/CEO


Dr. Abdelatif Chenite, PhD CTO


Dr. Cyril Chaput, PhD, MBA VP  RA/QA


Mrs. Monique Jarry VP Finance & Corporate Development


Dr. Yves De Backer VP Europe & Other Countries Markets


Marwane Berrada VP Business Development, North American Markets


Sam Alexandre Selmani VP Marketing

Contact us

Don’t hes­i­tate to con­tact us for any enquiries you might have.

500 Cartier Blvd. № 113, Laval

(+1) 450-680-3371


Your Name (required)

Your Email (required)


Your Message